Gabrielle Masson
Gabrielle Masson covers the business of biopharma through the details of the science, anchoring market moves in clinical data, trial design and patient outcomes. At BioSpace she follows drug developers from early-stage biotechs to global pharmas, with a particular focus on how study readouts, competitive benchmarks and regulatory decisions translate into winners and losers across the sector.
Biopharma business through trial readouts and competitive benchmarks
Masson’s coverage treats business news and clinical evidence as a single story rather than two separate tracks. In pieces such as her report on Relay Therapeutics’ data outpacing a Novartis program in a rare disease, she leads with response rates, safety profiles and trial design choices, then ties those numbers to strategic positioning and valuation implications. She is quick to compare new data against existing standards of care or rival assets, spelling out how a percentage point shift in efficacy or tolerability changes the commercial outlook. Company statements and investor-friendly language take a back seat to concrete metrics, with clear explanations of what constitutes a meaningful effect size in a given indication. This approach makes her business reporting especially useful when a story hinges on the strength of a dataset rather than the size of a headline deal.
Oncology, rare disease and targeted therapies
Within the broader life science business beat, Masson gravitates toward oncology, rare disease and other targeted therapies where mechanism and mutation matter. Many of her stories spotlight precision medicines and next-generation modalities—small biotechs trying to displace entrenched incumbents, or large pharmas recalibrating pipelines around specific biomarkers. She pays attention to niche populations, mutation-defined subgroups and lines of therapy, noting how these factors expand or constrain a product’s addressable market. When a program succeeds or fails, her copy makes clear whether the turning point is biology, trial execution, regulatory expectations or competitive timing. For teams working in tightly defined indications, her reporting reflects an understanding that “rare” markets can still carry outsized strategic weight.
Deals, restructurings and financing moves across the sector
Masson regularly tracks the money flows that shape biopharma’s pipeline—licensing agreements, M&A, collaboration deals, as well as layoffs, strategic resets and asset prioritizations. Her deal coverage stresses what each side contributes and gains, highlighting pipeline gaps, geographic reach or platform capabilities that motivate a transaction. In restructuring and workforce stories, she connects job cuts and program discontinuations back to specific clinical disappointments, shifting therapeutic priorities or broader market pressure, rather than treating them as isolated cost-saving moves. She also follows capital-raising events, from venture rounds to public offerings, outlining how new funding is earmarked across lead programs and earlier-stage assets. The through-line is a consistent effort to link financial decisions to scientific risk and portfolio strategy.
Fast-turn, release-driven news with clear, concise language
Most of Masson’s work is short to mid-length news coverage driven by company announcements, regulatory filings and conference data drops. Her pieces move quickly from the basic who/what/when into the why it matters, with minimal adornment and a preference for plain, direct sentences. She selects key quotes from executives sparingly, using them to illuminate strategy rather than to fill space, and she avoids hype-laden language even when reporting strong results. Timeliness is central to her role, but her stories retain enough context—prior readouts, earlier setbacks, competitor status—that they stand as a useful record after the initial news cycle passes. For communications teams, this combination of speed, data fluency and emphasis on concrete impact defines how she approaches biopharma business stories.
4 more business journalists.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex Smith
Alex Smith focuses on the business impact of enterprise technology, with a distinctive emphasis on AI literacy and skills rather than technical specifications. They write for Technology Record, covering how artificial intelligence and cloud platforms from major providers are turned into concrete programmes for organisations and governments. Their beat sits at the junction of business strategy, national digital policy and large-scale technology partnerships. They report on national AI literacy programmes and public–private partnerships, showing how policy choices, vendor capabilities and skills gaps intersect. On the business beat, they treat AI and cloud as tools for competitiveness, workforce readiness and participation in a data-driven economy. Their concise, announcement-led reporting highlights who is partnering with whom, what programme is being launched, which technologies underpin it and how it changes capability on the ground for executive readers.
Alison Durkee
Alison Durkee focuses on how law, regulation and politics create business risks for major companies and industries. She is a reporter at Forbes, where she writes news-driven explainers on complex legal and regulatory developments and their impact on corporate strategy, reputation and markets. Her coverage centers on companies under scrutiny, especially in technology and other high-growth sectors, and tracks trials, investigations and fast-changing policy fights. She breaks down lawsuits, inquiries and regulatory moves into clear parts, grounded in timelines, filings and official actions. She reports on generative artificial intelligence and other emerging technologies as tests of legal frameworks and corporate risk management, explaining how issues like intellectual property, safety compliance, consumer protection and governance can reshape product roadmaps, partnerships and investor expectations.
Alyson Shontell
Alyson Shontell covers business through the lens of leadership, using in-depth conversations with powerful executives and founders to show how their decisions shape companies, markets, and public life. She is editor in chief at Fortune, overseeing coverage across the masthead while continuing to write selected high-impact pieces. Her core work is long, reported interviews and profiles of CEOs of large companies, dominant tech firms, and fast-growing startups. She focuses on how leaders think, manage risk, make unconventional calls, and handle crises, culture, and the future of work. Her subjects include corporate chiefs, startup founders, and political figures treated as executives. She probes operating detail, governance, internal culture, and trade-offs around growth, disruption, and workplace models, using concrete examples and direct, accessible prose that foregrounds the subject’s voice while pressing for specifics.